<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="197">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00003916</nctid>
  <trial_identification>
    <studytitle>Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma</studytitle>
    <scientifictitle>Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EORTC-22972</secondaryid>
    <secondaryid>EORTC-22972-26991</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain and Central Nervous System Tumors</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - radiation therapy
Treatment: other - stereotactic radiosurgery

Treatment: other: radiation therapy


Treatment: other: stereotactic radiosurgery


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Histologically proven WHO grade III or IV glioma at primary
        diagnosis that enhance on preoperative imaging Glioblastoma Anaplastic astrocytoma
        Gliosarcoma Tumor volume no greater than 4.0 cm in maximum diameter on preoperative CT or
        MRI No prior histology of WHO grade I or II glioma Astrocytoma Oligodendroglioma No
        brainstem or infratentorial tumor No multifocal glioma Safe to treat tumor stereotactically
        No close proximity to critical structures, e.g., optic chiasm

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: WHO 0 or 1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:
        Able to tolerate full course of conventional radiotherapy No prior or concurrent medical
        condition that would preclude study therapy No prior malignancies within 5 years except
        nonmelanomatous skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy No concurrent adjuvant chemotherapy Endocrine therapy: Concurrent steroids
        allowed Radiotherapy: See Disease Characteristics No prior radiotherapy to the head and
        neck area No prior radiotherapy to the brain No more than 6 weeks since other prior
        radiotherapy Surgery: See Disease Characteristics</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/1999</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer - EORTC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an
      effective treatment for patients with glioma. Stereotactic radiation therapy may be able to
      deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet
      known if standard radiation therapy is more effective when followed by stereotactic radiation
      therapy.

      PURPOSE: Randomized phase III trial to compare the effectiveness of standard radiation
      therapy with or without stereotactic radiation therapy in treating patients who have glioma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00003916</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Brigitta Baumert, MD, PhD</name>
      <address>UniversitaetsSpital Zuerich</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>